Abbott expects a ‘few hundred million’ in tariff costs in 2025

CEO Robert Ford told investors the company had considered raising its earnings forecast for 2025, but decided to maintain it in light of the new tariffs.

J&J’s electrophysiology sales dip amid slow Varipulse start

Johnson & Johnson’s electrophysiology unit struggled in the first quarter, as the company chases Medtronic and Boston Scientific in the red-hot pulsed field ablation market.

DaVita hit by ransomware attack

The kidney dialysis firm doesn’t have an estimate for how long disruption from the attack will last, though DaVita stressed it’s continuing to provide patient care.

J&J expects tariff charge of $400M this year

CFO Joe Wolk, who revealed the figure Tuesday morning on CNBC, told investors the charge was primarily in the healthcare giant’s medtech business.

Edwards receives CE mark for Sapien M3 mitral valve replacement device

The replacement system is launching into markets already served by repair devices, namely Edwards’ Pascal and Abbott’s Mitraclip.

US launches probe that could set stage for pharma tariffs

The Commerce Department has begun a so-called Section 232 investigation into the national security effects of the U.S. importing pharmaceuticals and their starting materials.

Updated April 14, 2025

US launches probe into semiconductor imports

The Section 232 investigation comes ahead of anticipated tariffs on the industry.

J&J completes first surgeries with Ottava robot

Johnson & Johnson plans to seek a U.S. indication for multiple general surgery procedures, including gastric bypass, which was performed in the clinical trial.

Tariffs top of mind for medtech firms this earnings season

GE Healthcare and Medtronic said they are preparing mitigation plans as they assess the potential ramifications of Trump’s tariff policies.

Cepheid to lay off 167 people in California

The company laid off more than 1,300 people in California in 2023 and 2024 as respiratory sales fell from the peak hit during the pandemic.

Pharma bosses face down investor angst on tariffs, HHS chaos

As first quarter earnings begin, executives are confronting market turmoil, regulatory instability and the threat of U.S. tariffs on their products.

Late-stage digital health funding rebounds in Q1: Rock Health

The median deal size for late-stage funding rounds was $105 million, nearly double the $55 million check size across 2024.

Intuitive wins FDA clearance for single-port robotic surgery stapler

CFO Jamie Samath said in January that the stapler clearance would trigger the start of “broad commercial efforts” for the single-port system.

Tariff turmoil: Hospitals, device makers welcome pause, but fear long-term pain

Healthcare providers and medtech companies still face pressure to find ways to offset potential supply chain shocks despite the latest about-face in President Donald Trump’s tariff wars.